-Bloomberg
Cantor Fitzgerald Reiterates Neutral on TherapeuticsMD, Announces $1 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates TherapeuticsMD (NASDAQ:TXMD) with a Neutral and announces $1 price target.
Related Posts
Powell Industries Q4 GAAP EPS $0.28 Up From $0.25 YoY, Sales $129.46M Beat $116.09M Estimate
Powell Industries (NASDAQ:POWL) reported quarterly earnings of $0.28 per share. This is a 12 percent increase over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of
Gracell Biotech’s Multiple Myeloma Candidate Shows 100% Response Rate In Newly Diagnosed Candidates
Gracell Biotechnologies Inc (NASDAQ:GRCL) announced the clinical data from its ongoing Phase 1 investigator-initiated trial (IIT) in China evaluating GC012F as…
DigitalBridge Group Reports $100M Investment From Int’l. Finance Corp. In Digital Infrastructure Assets Managed By Co. In Brazil, Indonesia, Malaysia
DigitalBridge Group, Inc. (NYSE:DBRG) (“DigitalBridge” or the “Company”) today announced that the International Finance Corporation (“IFC”) will be investing $100 million in digital